Immunotherapy brings hope for the complete cure of cancer by activating the human immune system to kill tumors. Currently, most approved immunotherapies show significant effects in hematological tumors, but have low response rates and poor efficacy in solid tumors. The main reason is the complex and highly heterogeneous tumor immune microenvironment in solid tumors, where … Read more
Primary liver cancer is a common malignant tumor in China, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and mixed hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA), with HCC accounting for 75% to 85% and ICC for 10% to 15%[1, 2]. Although the incidence of cholangiocarcinoma is low, its malignancy is very high, with most patients diagnosed at an advanced … Read more
Intrahepatic cholangiocarcinoma (ICC) is a lethal malignant tumor, with an incidence rate ranking second among primary liver cancers. In the past decade, the incidence of this disease has increased by 140%. ICC accounts for 20% of all liver malignancies, and 3% of all gastrointestinal malignancies. The disease typically develops against a background of chronic inflammation, … Read more
Hello everyone, today I would like to share an article published in the Journal of the American Society for Mass Spectrometry titled “Mass Spectrometry-Driven Epitope Mapping: Application of Diethylpyrocarbonate Covalent Labeling for the Immunotherapeutic Target Programmed Cell Death Protein 11“. The corresponding author of the article is Professor Patanachai K. Limpikirati from Chulalongkorn University in … Read more
Antibody-drug conjugates (ADCs) in antitumor therapy, also known as “biological missiles,” are a new type of drug that combines targeting and antitumor activity. By linking cytotoxic drugs to targeted drugs, when the targeted drug acts on the corresponding target, the drug enters the tumor cells through phagocytosis, causing lysis and releasing the cytotoxic drug to … Read more
01 In the treatment of non-small cell lung cancer (NSCLC), a subtype characterized by the deletion of the LKB1 gene has long left clinicians at a loss. These tumors are referred to as “immune deserts”—with almost no trace of anti-cancer T cells, they exhibit near-complete resistance to PD-1/PD-L1 immune checkpoint inhibitors (ICIs), resulting in poor … Read more
Introduction Gastric cancer remains a significant public health challenge globally, ranking fifth in incidence and mortality among all cancer types. In recent years, targeted therapy and immunotherapy have greatly improved survival for patients with gastric cancer/gastroesophageal junction cancer (GC/GEJC). However, there are few meaningful therapeutic targets in the field of gastric cancer, and the benefits … Read more
This article is reprinted from “Pharmaceutical Targeting“ Adjuvants are key components of many vaccines, enhancing the immunogenicity of antigens by improving the intensity, breadth, quality, and duration of the immune response. Since the approval of aluminum-based adjuvants by the U.S. Food and Drug Administration in 1939, the development of new adjuvants has progressed relatively slowly. … Read more
Jing Yuming Professor Deputy Chief Physician of Urology at Xijing Hospital. Academic Positions: Member of the Minimally Invasive and Robotic Surgery Group of the Urology Branch of the Chinese Medical Doctor Association, Member of the Urology and Male Reproductive Association of the China Medical Healthcare International Exchange Promotion Association, Vice Chairman of the Minimally Invasive … Read more
At the recent 2025 European Hematology Association (EHA) Annual Meeting and the International Conference on Malignant Lymphoma (ICML), not only were continuous breakthroughs in the field of lymphoma treatment witnessed, but a series of studies also validated the immense potential of precision immunotherapy in enhancing patient survival benefits. “Blood News” focuses on this international event, … Read more